Quince Therapeutics, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
QNCX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Blvd., Suite 273, South San Francisco, California

Insiders trading volume in the past year

Quince Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
David Lamond Director $6 M +$602 K +11.1% Jun 5, 2024
Stephen S. Dominy Chief Scientific Officer, Director $1.35 M Jan 3, 2022
Casey Lynch Chief Executive Officer, Director $1.11 M Jan 3, 2022
Dirk Thye CEO AND CHIEF MEDICAL OFFICER, Director $648 K +$210 K +48% Feb 1, 2024
Philip S. Low Director $488 K May 19, 2022
Christopher P. Lowe Interim CEO, COO & CFO $249 K Mar 3, 2022
Karen L. Smith Chief Medical Officer $183 K Feb 1, 2023
Brendan Hannah Chief Business Officer And Coo $142 K +$87.6 K +162% Jun 4, 2024
Leslie Holsinger EVP, Preclinical Development $139 K Jun 6, 2022
Michael J. Detke Chief Medical Officer $132 K Mar 3, 2022
Caryn Gordon McDowell Chief Legal & Adm. Officer $115 K Jun 6, 2022
Luca Benatti Director $75.4 K Jun 5, 2024
Charles S. Ryan President $69.6 K Feb 1, 2024
Ted Monohon Chief Accounting Officer & VP $25.8 K Mar 6, 2023
Guenter Janhofer Chief Scientific Officer $14.1 K Oct 23, 2023
Margaret McLoughlin Director $7.52 K +$9.84 K Jun 5, 2024
Marwan Sabbagh Director Mar 14, 2022
Una S. Ryan Director Jun 5, 2024
June Bray Director Jun 5, 2024
Rajiv Patni Director Jun 5, 2024
Christopher J. Senner Director Jun 5, 2024

Recent Insider Transactions by Companies or Individuals for Quince Therapeutics, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership